Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.71 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17554431 | 0.84 | LMNA (0.61) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL631673 | 0.84 | MAOB (0.79) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL27521276 | 0.84 | MAOB (0.77) | MAOBPARP10MAOANR4A2 | |
| SCHEMBL31114416 | 0.84 | MAOB (0.79) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL1379497 | 0.83 | MAOB (1.00) | MAOBPARP10GAAMAPTMAOA | |
| SCHEMBL21480309 | 0.83 | MAOB (0.64) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL810623 | 0.83 | MAOB (0.72) | MAOBMAPTMAOARAB9AL3MBTL1 | |
| SCHEMBL29638127 | 0.83 | MAOB (1.00) | MAOBPARP10GAAMAPTMAOA | |
| SCHEMBL13745098 | 0.82 | MRGPRX4 (0.62) | MAOBGAAMAPTMAOARAB9A | |
| SCHEMBL12533272 | 0.81 | MAOB (0.65) | MAOBGAAMAPTMAOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325156-A1 | HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF | RUI JIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2020-10-15 | — | — | US | disclosed |
| EP-3705481-A1 | HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF | Rui Jin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine (CN) | 2020-09-09 | — | — | EP | disclosed |
| WO-2019196111-A1 | ANTI-TUMOR MULTIDRUG RESISTANCE OF HETEROARYL AMIDE COMPOUND, USE IN TREATMENT OF CANCERS AND PROTEIN-DRUG MOLECULAR COMPLEX | 上海交通大学医学院附属瑞金医院 | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325156-A1 | HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF | WEE1, ABCG2, WEE2 | MAOB 1780/4885PARP10 1704/4885GAA 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.